. "Obecn\u011B odpov\u00EDdaly hl\u00E1\u0161en\u00E9 zn\u00E1mky a symptomy vystup\u0148ov\u00E1n\u00ED zn\u00E1m\u00FDch farmakologick\u00FDch \u00FA\u010Dink\u016F p\u0159\u00EDpravku, tj. ospalost a sedace, tachykardie a hypotenze.\nBylo hl\u00E1\u0161eno \u00FAmrt\u00ED pacienta v klinick\u00E9 studii po akutn\u00EDm p\u0159ed\u00E1vkov\u00E1n\u00ED 13,6 g a v poregistra\u010Dn\u00EDm sledov\u00E1n\u00ED v d\u00E1vce pouze 6 g samotn\u00E9ho kvetiapinu. Bylo v\u0161ak hl\u00E1\u0161eno i p\u0159e\u017Eit\u00ED po akutn\u00EDm p\u0159ed\u00E1vkov\u00E1n\u00ED a\u017E 30 g kvetiapinu. V poregistra\u010Dn\u00EDm obdob\u00ED bylo hl\u00E1\u0161eno p\u0159ed\u00E1vkov\u00E1n\u00ED samotn\u00FDm kvetiapinem s n\u00E1sledkem smrti nebo komatu. \nPacienti se z\u00E1va\u017En\u00FDm kardiovaskul\u00E1rn\u00EDm onemocn\u011Bn\u00EDm maj\u00ED vy\u0161\u0161\u00ED riziko ne\u017E\u00E1douc\u00EDch projev\u016F po p\u0159ed\u00E1vkov\u00E1n\u00ED (viz bod 4.4).\nL\u00E9\u010Dba p\u0159ed\u00E1vkov\u00E1n\u00ED\nKvetiapin nem\u00E1 \u017E\u00E1dn\u00E9 specifick\u00E9 antidotum. V p\u0159\u00EDpadech z\u00E1va\u017En\u00FDch p\u0159\u00EDznak\u016F je t\u0159eba v\u017Edy vz\u00EDt v \u00FAvahu mo\u017Enost sou\u010Dasn\u00E9 intoxikace n\u011Bkolika l\u00E9\u010Divy. Doporu\u010Duj\u00ED se postupy intenzivn\u00ED p\u00E9\u010De, v\u010Detn\u011B zaji\u0161t\u011Bn\u00ED a udr\u017Eov\u00E1n\u00ED pr\u016Fchodnosti d\u00FDchac\u00EDch cest, zabezpe\u010Den\u00ED adekv\u00E1tn\u00EDho p\u0159\u00EDsunu kysl\u00EDku a ventilace a monitorov\u00E1n\u00ED a podpora kardiovaskul\u00E1rn\u00EDho syst\u00E9mu. \nA\u010Dkoli nejsou k dispozici \u00FAdaje o prevenci vst\u0159eb\u00E1n\u00ED l\u00E9ku p\u0159i p\u0159ed\u00E1vkov\u00E1n\u00ED, m\u016F\u017Ee b\u00FDt u z\u00E1va\u017En\u00E9 otravy zva\u017Eov\u00E1na gastrick\u00E1 lav\u00E1\u017E, pokud mo\u017Eno provedena do 1 hodiny po po\u017Eit\u00ED. M\u016F\u017Ee b\u00FDt zv\u00E1\u017Eeno tak\u00E9 pod\u00E1n\u00ED aktivn\u00EDho uhl\u00ED\nRefraktern\u00ED hypotenzi v p\u0159\u00EDpadech p\u0159ed\u00E1vkov\u00E1n\u00ED kvetiapinem je t\u0159eba l\u00E9\u010Dit vhodn\u00FDm zp\u016Fsobem, nap\u0159. intraven\u00F3zn\u00EDm pod\u00E1n\u00EDm tekutin a/nebo sympatomimetik (nejsou vhodn\u00E9 adrenalin a dopamin, nebo\u0165 stimulace beta receptor\u016F m\u016F\u017Ee zhor\u0161ovat hypotenzi p\u0159i sou\u010Dasn\u00E9 blok\u00E1d\u011B alfa receptor\u016F kvetiapinem).\nPe\u010Dliv\u00FD l\u00E9ka\u0159sk\u00FD dohled a monitorov\u00E1n\u00ED mus\u00ED pokra\u010Dovat a\u017E do \u00FApln\u00E9ho vyl\u00E9\u010Den\u00ED pacienta.\n"@cs . . . . . . . . "4.9 P\u0159ed\u00E1vkov\u00E1n\u00ED"@cs . "004.009" .